Headlines about Opko Health (NASDAQ:OPK) have trended somewhat positive on Sunday, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Opko Health earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.9660681523921 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the media stories that may have impacted Accern’s analysis:

Shares of Opko Health (OPK) opened at 6.13 on Friday. The company’s 50 day moving average price is $6.24 and its 200-day moving average price is $6.97. Opko Health has a 1-year low of $5.85 and a 1-year high of $12.15. The company’s market capitalization is $3.43 billion.

Opko Health (NASDAQ:OPK) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The company had revenue of $314.20 million for the quarter, compared to the consensus estimate of $322.64 million. Opko Health had a negative return on equity of 3.67% and a negative net margin of 6.52%. Opko Health’s quarterly revenue was down 12.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.02 earnings per share. On average, equities analysts forecast that Opko Health will post ($0.20) earnings per share for the current year.

OPK has been the topic of several analyst reports. BidaskClub raised Opko Health from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and set a $19.50 target price on shares of Opko Health in a research report on Friday, June 16th. Zacks Investment Research cut Opko Health from a “buy” rating to a “hold” rating in a research report on Saturday, August 12th. Jefferies Group LLC reissued a “hold” rating and issued a $6.50 price objective (down previously from $6.80) on shares of Opko Health in a research report on Thursday, August 10th. Finally, Barrington Research boosted their price objective on Opko Health to $11.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. Opko Health presently has an average rating of “Buy” and an average price target of $15.28.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/10/opko-health-opk-earning-somewhat-positive-media-coverage-analysis-shows.html.

In other Opko Health news, CEO Phillip Md Et Al Frost acquired 21,800 shares of the stock in a transaction dated Tuesday, June 27th. The shares were acquired at an average cost of $6.77 per share, for a total transaction of $147,586.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $20,776,798.27. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have purchased 1,050,300 shares of company stock worth $6,671,904 over the last quarter. 40.19% of the stock is owned by company insiders.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.